Cargando…

Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study

OBJECTIVES: Low bone mineral density (BMD) was recently identified as a novel risk factor for patients with hepatocellular carcinoma (HCC). In this multicenter study, we aimed to validate the role of BMD as a prognostic factor for patients with HCC undergoing transarterial chemoembolization (TACE)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Lukas, Mähringer-Kunz, Aline, Auer, Timo Alexander, Fehrenbach, Uli, Gebauer, Bernhard, Haubold, Johannes, Theysohn, Jens M., Kim, Moon-Sung, Kleesiek, Jens, Diallo, Thierno D., Eisenblätter, Michel, Bettinger, Dominik, Steinle, Verena, Mayer, Philipp, Zopfs, David, Pinto dos Santos, Daniel, Kloeckner, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Interventional
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889510/ https://www.ncbi.nlm.nih.gov/pubmed/35986768 http://dx.doi.org/10.1007/s00330-022-09069-8

Ejemplares similares

Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems
por: Müller, Lukas, et al.
Publicado: (2022)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
por: Bargellini, Irene, et al.
Publicado: (2021)

Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE
por: Fronda, Marco, et al.
Publicado: (2021)

Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE
por: Kong, Chunli, et al.
Publicado: (2021)

Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC
por: Müller, Lukas, et al.
Publicado: (2022)

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
por: Jin, Zhi-Cheng, et al.
Publicado: (2023)

Vascular anomalies of the celiac trunk and implications in treatment of HCC with TACE. Description of a case and review of the literature
por: Roma, Silvia, et al.
Publicado: (2019)

Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
por: Müller, Lukas, et al.
Publicado: (2022)

Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide
por: Müller, Lukas, et al.
Publicado: (2021)

European Multicenter Study on Degradable Starch Microsphere TACE: The Digestible Way to Conquer HCC in Patients with High Tumor Burden
por: Ludwig, Johannes M., et al.
Publicado: (2021)

Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Müller, Lukas, et al.
Publicado: (2021)

Visceral artery aneurysms: Incidence, management, and outcome analysis in a tertiary care center over one decade
por: Pitton, Michael B., et al.
Publicado: (2015)

Outcome of conventional transarterial chemoembolization (cTACE) in the management of spontaneously ruptured hepatocellular carcinoma
por: Patidar, Yashwant, et al.
Publicado: (2019)

TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension
por: Qiu, Zhenkang, et al.
Publicado: (2022)

Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC—A Proof-of-Concept Study
por: Stoehr, Fabian, et al.
Publicado: (2022)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
por: Bettinger, Dominik, et al.
Publicado: (2018)

Transjugular intrahepatic portosystemic shunt placement: portal vein puncture guided by 3D/2D image registration of contrast-enhanced multi-detector computed tomography and fluoroscopy
por: Meine, Timo C., et al.
Publicado: (2020)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India
por: Paul, Shashi Bala, et al.
Publicado: (2011)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Liu, Shanshan, et al.
Publicado: (2023)

The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT
por: Sun, HongLiang, et al.
Publicado: (2017)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
por: Kinzler, Maximilian N., et al.
Publicado: (2023)

Impact of interventionalist’s experience and gender on radiation dose and procedural time in CT-guided interventions—a retrospective analysis of 4380 cases over 10 years
por: Theilig, Dorothea, et al.
Publicado: (2020)

The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study
por: Mähringer-Kunz, Aline, et al.
Publicado: (2021)

Arthroscopic assessment of concomitant intraarticular pathologies in patients with osteonecrosis of the femoral head
por: Serong, Sebastian, et al.
Publicado: (2020)

Published trials of TACE for HCC are often not registered and subject to outcome reporting bias
por: Grégory, Jules, et al.
Publicado: (2020)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
por: Sun, Tao, et al.
Publicado: (2023)

Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection
por: Lüdemann, Willie, et al.
Publicado: (2022)

Gd-EOB MRI for HCC subtype differentiation in a western population according to the 5(th) edition of the World Health Organization classification
por: Auer, Timo A., et al.
Publicado: (2023)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Transaneurysmal Occlusion of Complicated Common Femoral Artery Pseudoaneurysms Using the Angio-Seal Closure Device—A Promising Technique
por: Auer, Timo A., et al.
Publicado: (2022)

Innovative multi-modality imaging to assess paravalvular leak
por: Isorni, Marc-Antoine, et al.
Publicado: (2019)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
por: Luz, Jose Hugo Mendes, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sd47ibneaubqvv0p2mg0a4a4e5